Suppr超能文献

发现和评价新型硝二氢咪唑恶唑类化合物作为有前途的抗结核药物。

Discovery and evaluation of novel nitrodihydroimidazooxazoles as promising anti-tuberculosis agents.

机构信息

Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Changzhou Yinsheng Pharmacy Co., Ltd., Weitang Chemical Industry Zone, Changzhou 213000, China.

Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Bioorg Med Chem Lett. 2019 Sep 1;29(17):2511-2515. doi: 10.1016/j.bmcl.2019.06.055. Epub 2019 Jun 28.

Abstract

New analogues of antitubercular drug Delamanid were prepared, seeking drug candidates with enhanced aqueous solubility and high efficacy. The strategy involved replacement of phenoxy linker proximal to the 2-nitroimidazooxazole of Delamanid by piperidine fused 5 or 6-membered ring heterocycles (ring A). The new compounds were all more hydrophilic than Delamanid, and several class of analogues showed remarkable activities against M. bovis. And among these series, the tetrahydro-naphthyridine-linked nitroimidazoles displayed excellent antimycobacterial activity against both replicating (MABA) and nonreplicating (LORA) M. tb H37Rv and low cytotoxicity. Compared to Delamanid, these new compounds (6, 7, 45) demonstrated dramatically improved physicochemical properties and are suitable for further in vitro and in vivo evaluation.

摘要

新型抗结核药物德拉马尼类似物被制备,旨在寻找具有增强的水溶性和高效性的候选药物。该策略涉及用哌啶稠合的 5 或 6 元环杂环(环 A)替代德拉马尼中靠近 2-硝基咪唑并恶唑的苯氧基连接基。新化合物均比德拉马尼更亲水,并且几类类似物对牛分枝杆菌显示出显著的活性。在这些系列中,四氢-萘啶连接的硝基咪唑类化合物对复制(MABA)和非复制(LORA)的 H37Rv 结核分枝杆菌具有优异的抗分枝杆菌活性和低细胞毒性。与德拉马尼相比,这些新化合物(6、7、45)表现出显著改善的物理化学性质,适合进一步的体外和体内评估。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验